Hengrui’s ribupatide achieved up to 17.7% weight loss at 48 weeks in the Phase 3 GEMINI-1 trial, with gastrointestinal events as the main tolerability finding.
Written By: Charvi Kalal, PharmD
Reviewed By: Pharmacally Editorial Team
JAMA published Phase 3 GEMINI-1 trial results on November 15, 2026, showing that Jiangsu Hengrui Pharmaceuticals’ once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist ribupatide (HRS9531) produced significantly greater weight reduction than placebo in adults with overweight or obesity without diabetes. The randomized, double-blind, placebo-controlled study evaluated three doses over 48 weeks.
About Ribupatide and GEMINI-1
Ribupatide is a chemically synthesized, 39-amino acid dual GIP and GLP-1 receptor agonist developed for weight reduction. Its approximately seven-day terminal half-life supports once-weekly administration.
The trial (NCT06396429) enrolled 567 adults across 55 sites in China. Participants had a body mass index (BMI) of at least 28, or at least 24 with one or more weight-related comorbidities. Participants were randomized to receive ribupatide 2 mg (n=142), 4 mg (n=141), 6 mg (n=141) or placebo (n=143).
Treatment began at 1 mg once weekly, with dose increases of 1 mg every four weeks until the assigned target dose was reached. All participants received lifestyle interventions, including dietary counseling and at least 150 minutes of moderate-intensity exercise weekly. Overall, 514 participants (90.7%) completed the 48-week treatment period.
Ribupatide Achieved Up to 17.7% Weight Reduction
At week 48, least-squares mean body weight reductions were 10.7%, 16.4% and 17.7% with ribupatide 2 mg, 4 mg and 6 mg, respectively, compared with 1.4% with placebo. The corresponding placebo-adjusted differences were 9.3, 15.0 and 16.3 percentage points, respectively (P<.001 for all comparisons).
The proportion of participants achieving at least 5% weight reduction was 68.1% with 2 mg, 88.0% with 4 mg and 85.7% with 6 mg, compared with 16.0% with placebo. More substantial weight reductions were also observed. At least 20% weight loss was achieved by 44.4% of participants receiving 6 mg, compared with 3.5% in the placebo group.
Waist circumference decreased by 8.9 cm, 13.4 cm and 14.4 cm across the three ribupatide doses, respectively, compared with 2.5 cm with placebo. These findings indicate substantial reductions in body weight and central adiposity over 48 weeks.
Cardiometabolic Improvements Accompanied Weight Loss
Ribupatide treatment was also associated with improvements in several cardiometabolic measures. Placebo-adjusted reductions in systolic blood pressure ranged from 7.1 to 8.7 mm Hg, while HbA1c decreased by 0.32 to 0.47 percentage points. Triglyceride reductions ranged from 28.6% to 36.6%, alongside improvements in insulin resistance.
Exploratory analyses also showed reductions in high-sensitivity C-reactive protein and urinary albumin-to-creatinine ratio. However, these additional findings were not adjusted for multiplicity and should be interpreted as supportive rather than confirmatory evidence. The trial did not establish cardiovascular or renal outcome benefits.
Gastrointestinal Events Were the Most Common Adverse Events
Gastrointestinal disorders were more frequent with ribupatide than placebo, occurring in 47.9%, 58.2% and 63.1% of participants receiving 2 mg, 4 mg and 6 mg, respectively, compared with 23.1% with placebo. Diarrhea, nausea, vomiting and decreased appetite were the most commonly reported events. Most gastrointestinal events were mild to moderate and occurred mainly during dose escalation.
Serious adverse events occurred in 1.4%, 5.0% and 4.3% of the respective ribupatide groups versus 5.6% with placebo. Adverse events leading to permanent treatment discontinuation were uncommon, affecting 0.7% to 1.4% of ribupatide-treated participants. No deaths or cases of acute pancreatitis were reported.
Three cases of cholecystitis and three cases of papillary thyroid cancer were reported in the ribupatide groups. Investigators considered the thyroid cancer events probably unrelated to treatment. The relatively small number of events and limited treatment duration prevent definitive conclusions about uncommon or long-term safety risks.
Clinical Interpretation and Development Outlook
The GEMINI-1 findings provide Phase 3 evidence of substantial weight reduction with once-weekly ribupatide in Chinese adults with overweight or obesity without diabetes. The 4-mg and 6-mg doses produced numerically greater weight reductions than 2 mg, although the study did not directly compare ribupatide with other anti-obesity medicines.
An exploratory dual-energy x-ray absorptiometry (DXA) substudy involving 76 participants showed reductions in both fat mass and lean mass. Median lean-mass reductions were 12.0% with 4 mg and 15.2% with 6 mg, compared with 3.3% with placebo. Although fat-mass reductions were greater, the lean-mass findings warrant further evaluation. Muscle strength and objective physical performance were not directly assessed in this substudy.
The findings also have limitations. Participants were relatively young, with a mean age of 34.4 years, predominantly Han Chinese, and none had diabetes. The manufacturer participated in study design, conduct, data analysis and manuscript preparation. Furthermore, the 48-week study did not establish the durability of weight reduction after treatment discontinuation or long-term cardiovascular benefits. Cross-trial comparisons with other obesity medicines cannot establish comparative efficacy.
Hengrui is evaluating ribupatide further in an ongoing cardiovascular outcomes trial involving people with atherosclerotic cardiovascular disease (NCT07551492). Longer-term studies will be important to establish the durability of weight reduction, safety and potential effects on cardiovascular outcomes.
Reference
Zhao L, Chen Y, Cheng Z, et al. Once-Weekly Ribupatide for Weight Loss in Adults in China with Overweight or Obesity: The GEMINI-1 Randomized Clinical Trial. JAMA. November 15, 2026, doi: 10.1001/jama.2026.24796
To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects with Overweight or Obese, ClinicalTrials.gov ID NCT06396429
About the Writer
Charvi Kalal (LinkedIn) is a Pharm.D intern and aspiring medical writer with hands-on experience in medical writing, clinical research, pharmacovigilance, and clinical pharmacy. She has experience in medical content writing through CliMed, along with exposure to ADR monitoring, prescription analysis, patient counselling, literature review, and research documentation. Her research focuses on ADR monitoring and reporting in breast cancer patients receiving targeted therapy. With certifications in GCP, biomedical research, scientific writing, and clinical research, she is passionate about transforming scientific evidence into accurate, engaging, and accessible healthcare content.
